Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06326008
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-03-10
Brief Title:
Safety Tolerability and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for rr B-ALL a Clinical Trial
Sponsor:
Beijing GoBroad Hospital
Organization:
Beijing GoBroad Hospital
Organization Data
Organization:
Beijing GoBroad Hospital
Class:
OTHER
Study ID:
BJGBYY-IIT-LCYJ-2023-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Beijing GoBroad Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Jing Pan
Responsible Party Title:
Director of Dept of Hemato-Oncology and Immunotherapy
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Beijing GoBroad Hospital
Old Name:
None
Old Organization:
None